BMT and Cancer Immunotherapy Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Bone Marrow Transplant. 2010 Jul;45(7):1189-96. doi: 10.1038/bmt.2009.331. Epub 2009 Nov 30.
The influence of graft composition on the outcome of reduced-intensity (RIC) allogeneic PBSC transplantation (allo-PBSC) remains controversial. In this study, we analyzed the impact of CD34+ cell dose on the incidence of GVHD, and on the outcome after allo-PBSC, in 103 patients with hematological malignancies, using a uniform RIC regimen. The following variables were included in statistical analysis: (1) number of C34+ cells, (2) high-risk vs low-risk disease status, (3) matched related vs matched unrelated donor, (4) female donor to male recipient vs any other combination, (5) age of recipient (above vs below the median). Univariate and multivariate analysis did not reveal any association between CD34+ cell dose and acute grade-2 to grade-4, cGVHD, non-relapse mortality (NRM), relapse rate (RR) and OS. High-risk disease status was the only variable independently associated with increased NRM (P=0.001), increased RR (P=0.012) and decreased OS (P<0.001). The same results were obtained when analysis was restricted to a subgroup of 55 patients with myeloid neoplasms. The influence of graft composition on the outcome of RIC allo-PBSC should be further investigated via well-controlled randomized prospective studies.
移植物组成对低强度(RIC)异基因 PBSC 移植(allo-PBSC)结局的影响仍存在争议。在这项研究中,我们使用统一的 RIC 方案,分析了 103 例血液系统恶性肿瘤患者中 CD34+细胞剂量对 GVHD 发生率以及 allo-PBSC 后结局的影响。在统计分析中包括以下变量:(1)C34+细胞数量,(2)高危与低危疾病状态,(3)匹配相关供体与匹配无关供体,(4)女性供体给男性受者与任何其他组合,(5)受者年龄(高于或低于中位数)。单因素和多因素分析均未显示 CD34+细胞剂量与急性 2 至 4 级、cGVHD、非复发死亡率(NRM)、复发率(RR)和 OS 之间存在任何关联。高危疾病状态是唯一与增加 NRM(P=0.001)、增加 RR(P=0.012)和降低 OS(P<0.001)相关的独立变量。当将分析限制在 55 例骨髓增生性肿瘤患者的亚组中时,也得到了相同的结果。需要通过精心设计的前瞻性随机对照研究进一步探讨移植物组成对 RIC allo-PBSC 结局的影响。